Skip to main content
Premium Trial:

Request an Annual Quote

PierianDx, Cancer Genetics Partner on Precision Cancer Medicine Offering

NEW YORK (GenomeWeb) – Bioinformatics startup PierianDx announced today that it has partnered with Cancer Genetics to join their respective technologies into a precision oncology testing and analysis offering.

Under the alliance, the companies will combine Cancer Genetics' Focus::NGS tests — which use next-generation sequencing to provide insights into the genetics underlying solid tumors and hematologic malignancies — with PierianDx's Clinical Genomics WorkSpace software for NGS data management.

Additional terms of the deal were not disclosed.

"The combined capabilities allow physicians to seamlessly link the genetic profile of each patient to approved therapies and clinical trials, enabling the potential for improved outcomes," Cancer Genetics interim CEO John Roberts said in a statement.